Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 607 participants.
Also called NCT01734785
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 607 participants
- Registry
-
NCT01734785 -
2012-002270-31
-
- Other papers using this trial's data
- Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Brazil, Canada, El Salvador, France, New Zealand, Norway, South Korea, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01734785. Randomized; double masking; primary purpose treatment. Start 2013-02-08 (actual); primary completion 2015-03-23 (actual). Results posted on 2016-04-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Empagliflozin + Linagliptin
- Intervention (Drug)
- Empagliflozin + Linagliptin
- Intervention (Drug)
- Empagliflozin + Linagliptin
- Intervention (Drug)
- Empagliflozin placebo + Linagliptin placebo
- Intervention (Drug)
- Empagliflozin + Linagliptin
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01734785- Content hash
090f61256c491add15ae3ae6faa25365f02706244c743b3cf8a0a9bc3518922c